home / stock / cinc / cinc quote
Last: | $29.06 |
---|---|
Change Percent: | -0.38% |
Open: | $29.17 |
Close: | $29.06 |
High: | $29.35 |
Low: | $29.02 |
Volume: | 6,349,776 |
Last Trade Date Time: | 02/23/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$29.06 | $29.17 | $29.06 | $29.35 | $29.02 | 6,349,776 | 02-23-2023 |
$29.2 | $29.12 | $29.2 | $29.43 | $28.945 | 2,068,271 | 02-22-2023 |
$29.15 | $29.38 | $29.15 | $29.389 | $29.02 | 1,425,052 | 02-21-2023 |
$29.33 | $29.52 | $29.33 | $29.62 | $29.28 | 335,939 | 02-20-2023 |
$29.33 | $29.52 | $29.33 | $29.62 | $29.28 | 335,939 | 02-17-2023 |
$29.38 | $29.33 | $29.38 | $29.57 | $29.28 | 114,110 | 02-16-2023 |
$29.56 | $29.32 | $29.56 | $29.58 | $29.27 | 86,710 | 02-15-2023 |
$29.39 | $29.48 | $29.39 | $29.68 | $29.29 | 165,982 | 02-14-2023 |
$29.49 | $29.27 | $29.49 | $29.54 | $29.14 | 212,372 | 02-13-2023 |
$29.33 | $29.22 | $29.33 | $29.39 | $29.07 | 309,394 | 02-10-2023 |
$29.31 | $29.44 | $29.31 | $29.52 | $29.25 | 214,479 | 02-09-2023 |
$29.26 | $29.25 | $29.26 | $29.38 | $29.2 | 217,889 | 02-08-2023 |
$29.32 | $29.2 | $29.32 | $29.44 | $29.1 | 188,487 | 02-07-2023 |
$29.22 | $29.15 | $29.22 | $29.25 | $29.05 | 295,726 | 02-06-2023 |
$29.16 | $28.94 | $29.16 | $29.16 | $28.93 | 418,899 | 02-03-2023 |
$29.04 | $28.91 | $29.04 | $29.14 | $28.84 | 229,099 | 02-02-2023 |
$28.89 | $29.06 | $28.89 | $29.16 | $28.75 | 361,839 | 02-01-2023 |
$28.93 | $28.91 | $28.93 | $29.055 | $28.84 | 447,467 | 01-31-2023 |
$28.9 | $28.81 | $28.9 | $28.969 | $28.78 | 342,768 | 01-30-2023 |
$28.8 | $28.81 | $28.8 | $29.01 | $28.745 | 235,227 | 01-27-2023 |
News, Short Squeeze, Breakout and More Instantly...
CinCor Pharma Inc. Company Name:
CINC Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat ...
NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Oak Street Health, Inc. (NYSE:...
NEW YORK, NY / ACCESSWIRE / January 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ:CINC)'...